Skip to main content
. 2017 Jul 27;8(65):108548–108555. doi: 10.18632/oncotarget.19625

Figure 3. Relationship between STMN1 expression and benefit from adjuvant chemotherapy (ACT).

Figure 3

In all patients, (A) ACT vs Non-ACT. (B) STMN1 low vs high in patients with ACT. (C) ACT vs Non-ACT in STMN-low patients. In TNM III- IV stage patients, (D) ACT vs Non-ACT. (E) STMN low vs high in patients with ACT. (F) ACT vs Non-ACT in STMN1-low patients.